Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | MT-CO2 | P00403 | 2/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | PLG | P00747 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | CTSG | P08311 | 1/20 | 0.46 |
| ▸ | CMA1 | P23946 | 1/20 | 0.46 |
| ▸ | CTRC | Q99895 | 1/20 | 0.46 |
| ▸ | GSK3A | P49840 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | EP300 | Q09472 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5770320 | 0.89 | ALDH1A1 (0.69) | ALDH1A1KMT2AMEN1TSHRSMN1; SMN2 | |
| SCHEMBL584720 | 0.89 | ALDH1A1 (0.69) | ALDH1A1KMT2AMEN1TSHRSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1749140 | 0.87 | ALDH1A1 (0.67) | ALDH1A1KMT2AMEN1TSHRSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1749922 | 0.87 | ALDH1A1 (0.67) | ALDH1A1KMT2AMEN1TSHRSMN1; SMN2 | |
| SCHEMBL7829113 | 0.82 | ALDH1A1 (0.93) | ALDH1A1KMT2AMEN1TSHRSMN1; SMN2 | |
| SCHEMBL8383160 | 0.82 | ALDH1A1 (1.00) | ALDH1A1KMT2AMEN1TSHRSMN1; SMN2 | |
| SCHEMBL8383162 | 0.82 | ALDH1A1 (1.00) | ALDH1A1KMT2AMEN1TSHRSMN1; SMN2 | |
| SCHEMBL3716740 | 0.82 | ALDH1A1 (0.93) | ALDH1A1KMT2AMEN1TSHRSMN1; SMN2 | |
| SCHEMBL6214056 | 0.80 | ALDH1A1 (0.62) | ALDH1A1KMT2AMEN1TSHRSMN1; SMN2 | |
| SCHEMBL17228300 | 0.80 | ALDH1A1 (0.62) | ALDH1A1KMT2AMEN1TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250221998-A1 | DISCOVERY OF COVALENT EGFR INHIBITOR THROUGH CYSTEINE 775 | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2025-07-10 | — | — | US | disclosed |
| EP-4504730-A1 | DISCOVERY OF COVALENT EGFR INHIBITOR THROUGH CYSTEINE 775 | Dana-Farber Cancer Institute, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| WO-2023196409-A1 | DISCOVERY OF COVALENT EGFR INHIBITOR THROUGH CYSTEINE 775 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-9856264-B2 | Isoquinolinesulfonyl derivative as RHO kinase inhibitor | MEDSHINE DISCOVERY INC. (CN) | 2018-01-02 | — | — | US | disclosed |
| EP-3138843-A1 | ISOQUINOLINESULFONYL DERIVATIVE AS RHO KINASE INHIBITOR | Medshine Discovery Inc. (CN) | 2017-03-08 | — | — | EP | disclosed |
| EP-3138843-A1 | ISOQUINOLINESULFONYL DERIVATIVE AS RHO KINASE INHIBITOR | Medshine Discovery Inc. (CN) | 2017-03-08 | — | — | EP | disclosed |
| US-20170037050-A1 | ISOQUINOLINESULFONYL DERIVATIVE AS RHO KINASE INHIBITOR | MEDSHINE DISCOVERY INC. (CN) | 2017-02-09 | — | — | US | disclosed |
| US-20170037050-A1 | ISOQUINOLINESULFONYL DERIVATIVE AS RHO KINASE INHIBITOR | MEDSHINE DISCOVERY INC. (CN) | 2017-02-09 | — | — | US | disclosed |
| EP-2780342-B1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO LTD (CN) | 2016-06-01 | — | — | EP | disclosed |
| US-9181277-B2 | Aminoquinazoline derivatives and their salts and methods of use | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-11-10 | — | — | US | disclosed |
| US-7598236-B2 | Diazabicyclic central nervous system active agents | ABBOTT LABORATORIES (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080097094-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | ABBOTT LABORATORIES (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080097094-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | ABBOTT LABORATORIES (US) | 2008-04-24 | — | — | US | disclosed |
| US-7319106-B2 | Diazabicyclic central nervous system active agents | ABBOTT LABORATORIES (US) | 2008-01-15 | — | — | US | disclosed |
| US-7319106-B2 | Diazabicyclic central nervous system active agents | ABBOTT LABORATORIES (US) | 2008-01-15 | — | — | US | disclosed |
| US-6809105-B2 | (CIS)-6-(3-PYRIDINYL)-3,6-DIAZABICYCLO(3.2.0) HEPTANE FOR EXAMPLE; ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, ATTENTION DEFICIT HYPERACTIVITY DISORDER, DEPRESSION, NICOTINIC WITHDRAWAL SYNDROME, TOURETTE'S SYNDROME, AND SCHIZOPHRENIA | ABBOTT LABORATORIES | 2004-10-26 | — | — | US | disclosed |
| US-20040186107-A1 | Diazabicyclic central nervous system active agents | ABBVIE INC. | 2004-09-23 | — | — | US | disclosed |
| EP-1284976-A2 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | Abbott Laboratories (US) | 2003-02-26 | — | — | EP | disclosed |
| US-20020019388-A1 | Diazabicyclic central nervous system active agents | ABBVIE INC. | 2002-02-14 | — | — | US | disclosed |
| WO-2001081347-A2 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | ABBOTT LABORATORIES (US) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080097094-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | GAP43, GABRE, CHRNA6 | ALDH1A1 1292/4885KMT2A 3832/4885MEN1 567/4885 |
| US-20020019388-A1 | Diazabicyclic central nervous system active agents | GAP43, GABRE, CHRNA6 | ALDH1A1 907/4885KMT2A 3815/4885MEN1 428/4885 |
| US-20040186107-A1 | Diazabicyclic central nervous system active agents | GAP43, GABRE, CHRNA6 | ALDH1A1 907/4885KMT2A 3815/4885MEN1 428/4885 |
| US-20170037050-A1 | ISOQUINOLINESULFONYL DERIVATIVE AS RHO KINASE INHIBITOR | ROCK1, ROCK2, CIT | ALDH1A1 3120/4885KMT2A 1298/4885MEN1 3330/4885 |
| US-20250221998-A1 | DISCOVERY OF COVALENT EGFR INHIBITOR THROUGH CYSTEINE 775 | EGFR, ERBB2, ERBB3 | ALDH1A1 2954/4885KMT2A 4002/4885MEN1 4677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.